

Resource Summary Report

Generated by PRECISE-TBI on Sep 2, 2026

Mouse Anti-Chicken Vinculin Monoclonal Antibody, Unconjugated, Clone VIN-11-5

RRID:AB_477617

Type: Antibody

Proper Citation

Sigma-Aldrich Cat# V4505, RRID:AB_477617

Antibody Information

URL: http://antibodyregistry.org/AB_477617

Proper Citation: Sigma-Aldrich Cat# V4505, RRID:AB_477617

Target Antigen: Vinculin

Host Organism: mouse

Clonality: monoclonal

Comments: Vendor recommendations: Immunofluorescence; Western Blot; Indirect Immunofluorescence, Western Blot

Antibody Name: Mouse Anti-Chicken Vinculin Monoclonal Antibody, Unconjugated, Clone VIN-11-5

Description: This monoclonal targets Vinculin

Target Organism: chicken, chickenavian, mouse, bovine, human

Clone ID: Clone VIN-11-5

Antibody ID: AB_477617

Vendor: Sigma-Aldrich

Catalog Number: V4505

Record Creation Time: 20231110T044352+0000

Record Last Update: 20260829T130400+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Chicken Vinculin Monoclonal Antibody, Unconjugated, Clone VIN-11-5.

No alerts have been found for Mouse Anti-Chicken Vinculin Monoclonal Antibody, Unconjugated, Clone VIN-11-5.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 58 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#).

Kumariya S, et al. (2026) Transcriptional control of PPP2CB by YAP1 and TEAD1 mediates AMPK inhibition and mTORC1 activation in vascular smooth muscle cells. *iScience*, 29(3), 114996.

Spindler J, et al. (2026) SLX4IP limits replication stress globally and at ALT telomeres. *The EMBO journal*, 45(12), 4176.

Milano L, et al. (2026) BRCA2-dependent maturation of nascent strands during DNA replication. *Molecular cell*, 86(8), 1427.

Ghuloum FI, et al. (2026) A Modular Bioinstructive Platform Reveals Mechanistic Insights into Additive-Free, Topography-Driven Osteogenesis. *Advanced healthcare materials*, 15(18), e04865.

Mao C, et al. (2026) DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer. *Cancer research*, 86(13), 3309.

Goldman A, et al. (2026) An LRRK2 variant blocks NCOA4 trafficking upon iron overload, leading to ferroptotic death. *Journal of cell science*, 139(14).

Fu Z, et al. (2026) Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer. *Cancer cell*.

Lei G, et al. (2026) Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. *Cell*.

Lei G, et al. (2025) Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. *Cancer cell*, 43(6), 1076.

Lavanderos B, et al. (2025) Rhotekin-1 is a novel interacting protein and regulator of TRPC6 activity. *The FEBS journal*, 292(16), 4353.

- Yu H, et al. (2025) Energy status orchestrates YTHDF1 phase separation and tumorigenesis. *Cell reports*, 44(11), 116466.
- Ho-Xuan H, et al. (2025) YTHDF proteins and m6A-RNA clients undergo autophagic turnover during contact inhibition. *Cell reports*, 44(9), 116188.
- Song W, et al. (2025) Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity. *Cell reports*, 44(10), 116433.
- Cigrang M, et al. (2025) Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. *Nature communications*, 16(1), 512.
- Madej M, et al. (2025) PUS10-induced tRNA fragmentation impacts retrotransposon-driven inflammation. *Cell reports*, 44(6), 115735.
- Ryu JE, et al. (2024) Circadian regulation of endoplasmic reticulum calcium response in cultured mouse astrocytes. *eLife*, 13.
- Mao C, et al. (2024) Unraveling ETC complex I function in ferroptosis reveals a potential ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers. *Molecular cell*, 84(10), 1964.
- Brock K, et al. (2024) A comparative analysis of paxillin and Hic-5 proximity interactomes. Cytoskeleton (Hoboken, N.J.).
- Zhang D, et al. (2024) Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. *EBioMedicine*, 105, 105212.
- Hao M, et al. (2024) In vivo CRISPR knockout screen identifies p47 as a suppressor of HER2+ breast cancer metastasis by regulating NEMO trafficking and autophagy flux. *Cell reports*, 43(2), 113780.